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Abstract
Background: Human papillomavirus (HPV) is one of the most common sexually transmitted pathogens. This
observational study was conducted to estimate the trend of hospitalization for genital warts (GWs) in the Veneto
region (Italy) from 2004 to 2015.
Methods: All patients with GWs were identified in the hospital discharge records of all public and accredited private
hospitals that related to Veneto residents and contained the ICD9-CM code 078.11 associated with a genital surgical
procedure (vulval/vaginal warts, penile warts and anal warts). Annual total and sex- and age-specific hospitalization
rates and trends were calculated and correlated with the different HPV vaccine coverage over the study period.
Results: An annual rate of 11.8 per 100,000 population (8.6 per 100,000 males, and 14.8 per 100,000 females) was
found, corresponding to 6076 hospitalizations for condyloma (53.3% vulval/vaginal, 35.8% anal, 8.3% penile, and 2.6%
both penile or vulval/vaginal and anal). Among females, the rate of overall GWs remained stable to 2007 (19.1 per
100,000), then dropped significantly, reaching a rate of 11.3 per 100,000 in 2015 (average annual percent changes
[AAPC]: -6.1%; 95% CI: -8.4; −3.7). For males, the overall rate increased over the study period (from 6.4 per 100,000 in
2004 to 10.8 per 100,000 in 2015; AAPC: 3.8%; 95% CI: 1.2; 6.4).
Among the potentially vaccinated females (12- to 20-year-olds) there was a 62.1% decrease in the number of vulval/
vaginal warts from the years 2010-2012 to the years 2013-2015 due to an increase in the HPV coverage rate. A similar
reduction among males was observed in the same period and the same age group for penile warts (−68.2%).
Conclusion: GWs have an important impact on the health services and data suggest that GW-related
hospitalization rates rapidly decline in a population with a high HPV vaccination coverage (about 75%).
Further efforts should be made to better clarify the epidemiological picture regarding HPV-related diseases,
with particular regard to sexual behavior.
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Background
Human papillomavirus (HPV) is one of the pathogens
most often transmitted sexually in the developed and de-
veloping world. Despite they can be associated with ma-
lignant lesions, the HPV types generally give rise to
benign changes such as genital warts (GWs), which are
benign epithelial mucosal tumors. About 90% of diag-
nosed GWs are associated to HPV types −6 and 11 [1].
GWs are an important public health issue in both sexes,
in European regions point to an estimated annual inci-
dence ranging from 142.0 to 191.1 per 100,000 females,
and from 147.6 to 167.7 per 100,000 males [2, 3]. The
peak incidence is between 20 and 24 years of age for
females, and between 25 and 29 years old in males
[4]. GWs are not life-threatening and are generally
not perceived as a serious condition, but they can
have an important impact in the quality of life of the
person affected [5].
Hospital discharge records can be useful for assessing
the reporting of cases of GW severe enough to warrant
admission to hospital [6]. In industrialized countries, the
percentages of GW patients that are hospitalized vary be-
tween approximatively 7% and 19% [7–9]. Patients are
only hospitalized in the more complex cases, mainly for
GWs requiring surgical removal [10]. The hospitalization
rate for GWs is clearly only the tip of the iceberg of the
burden of care for HPV-related diseases, but its quantifi-
cation is useful for assessing the effectiveness of any
prevention strategy.
HPV is highly contagious and barrier measures cannot
guarantee full protection. Even sexual intercourse with-
out penetration is considered sufficient for transmission
[11]. Only an effective vaccine against HPV can ensure
primary prevention of the infection. Two anti-HPV
vaccines have been developed and are currently used in
population vaccination programs in many countries.
Both have proved highly effective in preventing HPV 16
and 18, and the quadrivalent vaccine also protects
against the HPV types that cause 90% of GWs (i.e. types
6 and 11) [12, 13].
Since 2008, free anti-HPV vaccination (with a
quadrivalent vaccine against HPV 16 and 18, and 6
and 11 [4-HPV]) has been offered to all girls in the
Veneto region (Italy) in their 12th year of life, and since
2015 it has also been offered to males of the same age. It
remains available free of charge up until their 18th birth-
day, then vaccination is offered in co-payment to women
up to 46 years old and to men up to 26 years old. As at
December 2015, the mean vaccination rate against HPV
in the Veneto (Italy) was reportedly about 75%, for full
vaccination cycles [14].
The aim of the present study was to estimate the trend
of GW-related hospitalization rates, stratified by gender,
and to assess the impact of HPV vaccination.
Methods
We conducted this observational study in the Veneto re-
gion, which has a population of 4.9 million. We checked
the hospital discharge records (HDRs) related to Veneto
residents in all public and accredited private hospitals from
1 January 2004 to 31 December 2015, considering the fol-
lowing HDR data: date of birth, gender, place of residence,
date of admission, surgical and other procedures, and date
of discharge. Each HDR contained one primary (or first-
listed) diagnosis, and up to five secondary diagnoses based
on the codes of the International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM).
Hospital discharge records were considered if they con-
tained the ICD9-CM code 078.11 (condyloma acumina-
tum) in one of the six diagnosis fields. We analyzed only
GW-related hospitalizations that included the following
ICD9-CM surgical codes grouped by anatomical site: vul-
val/vaginal warts (ICD9-CM: 70-71 and 58.3), penile warts
(ICD9-CM: 64 and 58.3), and anal warts (ICD9-CM: 49).
The length of hospital stay was calculated as the days elap-
sing between the dates of admission and discharge for
regular admissions, or the number of admissions for day
hospital patients, and the mean hospital stay was calcu-
lated. For patients readmitted, only the first hospital stay
was considered. Data were obtained from the Regional
Statistics Office of Veneto Region.
Based on the total number of hospital admissions
concerning Veneto residents in each year considered,
specific annual GW-related hospitalization rates were
calculated by dividing the annual number of GW-related
hospitalizations by the population in the year considered
(according to the Veneto Regional Authority’s statistical
office), and expressing the rates as hospitalizations per
100,000 population.
Subjects were grouped by age at the time of their hos-
pital admission as follows: 12-20 years old (all women in
this age group were eligible for free vaccination at all
times during the study period), 21-27 years old, 28-47,
and 48+ years old.
The estimated HPV vaccination coverage among 12- to
20-year-olds increased year by year from 2008 onwards.
The study period was divided as follows: a) a pre-
vaccination period (2004-2006); b) an early HPV vaccination
period (2007-2009), when the coverage was still low (about
15% of the 12- to 20-year-old cohort); c) an intermediate
HPV vaccination period (2010-2012), when the coverage in
this age group reached about 43%; and d) a late HPV vac-
cination period (2013-2015), when it was about 75%.
It was impossible to estimate the coverage for other
birth cohorts.
Statistical analysis
The data were analyzed using Student’s t-test for con-
tinuous data and Pearson’s chi square test for categorical
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data, as appropriate. A p value <0.05 was considered
significant. The analyses were performed using the Stat-
istical Package for the Social Sciences (SPSS 22.0; SPSS
Inc., Chicago, IL, USA). Significant trends over the years
considered were assessed as average annual percent
changes (AAPC), a summary measure of the trend over
a given fixed interval that is computed as a weighted
average of the annual percent change (APC) emerging
from the joinpoint model, using weights equating to the
length of the APC interval. If an AAPC lies entirely
within a single joinpoint segment, the AAPC is the same
as the APC for that segment [15].
Results
From 1 January 2004 to 31 December 2015, there were
7456 hospitalizations associated with a diagnosis of con-
dyloma in one of the six diagnosis fields, 6651 of these
cases included a surgical code, which was potentially as-
sociated with a genital wart and could be grouped by
genital anatomical site in 6076 cases (Fig. 1).
The 6076 cases eligible for our analysis included 3924
females (64.6%). The sample of patients as a whole was a
median 32 years old (Interquartile Range [IQR] 25-42),
the females 31 (IQR 25-40), and the males 35 (IQR 28-
46). In 88.9% of cases they had been treated at a day
hospital and the mean hospital stay was 1.6 ± 2.0 days,
with no differences by gender or age group. Females
were admitted to a gynecology ward (3093 patients) or
to a general surgery ward (597 patients) in 94.0% of
cases. Males were admitted to a general surgery ward in
73.7% of cases (1585 patients) and to a urology ward in
20.1% (432 patients). The remainder of the sample was
admitted to other surgical wards. Overall, the ratio of
vulval/vaginal to penile warts was 6.0:1, while the male-
to-female ratio for anal warts was 2.5:1.
In the sample analyzed, 6076 patients received treat-
ment: 3237 of the females (82.5%) were treated for vul-
val/vaginal warts, and 507 of the males (23.6%) for
penile warts. An overall 2176 (35.8%) patients were
treated for anal warts (75.4% of the males, and 14.1% of
the females; p < 0.01); and 156 (2.6%) had combined
treatments. Table 1 shows the patients’ characteristics by
gender and type of treatment.
The overall annual GW-related hospitalization rate
during the study period was 11.8 per 100,000 population
(8.6/100,000 males, and 14.8/100,000 females). The rate
was stable among females up until 2007, with 19.1 hos-
pitalizations per 100,000 in 2007, then fell significantly,
reaching 11.3 per 100,000 hospitalizations for GWs in
2015 (AAPC: -6.1%; 95% CI: -8.4; −3.7). The overall
trend of GW-related hospitalizations rose significantly in
males over the study period, starting from 6.4 per
100,000 in 2004 and peaking in 2015 at 10.8 per 100,000
(AAPC: 3.8%; 95% CI: 1.2; 6.4). Figure 2 shows the GW-
related hospitalization rate by gender and anatomical
site, revealing a significantly declining trend for vulval/
vaginal and penile warts, (AAPC: -7.8%; 95% CI: -10.1;
−5.4 for vulval/vaginal warts; and AAPC: −4.8%; 95% CI:
-8.1; −1.4 for penile warts).
Overall, the differences in the GW-related hospitalization
rates for males between the periods 2004-2006 and 2007-
2009, and between the periods 2007-2009 and 2013-2015
were 46.3% and −2.1%, respectively. Among females, the
rate changed over the same periods by −0.7% and −41.0%,
respectively (Fig. 3).
Among the 12- to 20-year-olds (the age group eligible
for HPV vaccination according to our program), the
hospitalization rate for vulval/vaginal warts dropped
from 19.9/100,000 in the early vaccination period (2007-
2009) to 7.6/100,000 in the last study period (2013-
Fig. 1 Flowchart of GW-related hospitalizations selected
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2015), with a decrease of 62.1%. For penile warts in the
same age group, there was an even greater drop from
2007 to 2009 to 2013-2015 (−68.2%) (Fig. 3).
Figure 4 shows the rates anal warts by gender and
study period; the highest hospitalization rate for anal
warts concerned the 21- to 27-year-olds of both genders.
Discussion
This study examined the trends of the hospitalization
rates for GWs in a cohort of 5 million citizens and the
results show that the burden of HPV-related disease on
hospital resources is an important public health issue. It
is not easy to estimate the morbidity of HPV disease in
Table 1 Characteristics of the 6076 patients considered, by gender
Characteristics Males Females Total
n (%) n (%) n (%)
Age group
12-20 65 (3.0) 356 (9.1) 421 (6.9)
21-27 468 (21.7) 1120 (28.5) 1588 (26.1)
28-47 1154 (53.6) 2035 (51.9) 3189 (52.5)
48+ 465 (21.6) 413 (10.5) 878 (14.5)
Anatomical site
Penile or vulval/vaginal 507 (23.6) 3237 (82.5) 3744 (61.6)
Anal 1623 (75.4) 553 (14.1) 2176 (35.8)
Penile or vulval/vaginal and anal 22 (1.0) 134 (3.4) 156 (2.6)
Fig. 2 Overall GW-related hospitalization trends (× 100,000 population) in the Veneto region (2004-2015), by gender and anatomical site
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Fig. 3 Average annual hospitalization rates for vulval/vaginal and penile warts by period, and by age group
Fig. 4 Average annual hospitalization rates for anal warts by study period, age group and gender
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the general population due to differences in study design
and population profiles, access to health care, and clinical
data recording methods, especially for benign conditions.
In our sample, the overall hospitalization rate was
11.8/100,000 population per year, and it was 1.7 times
higher for females than for males. On analyzing the dif-
ferent periods of the study, however, the hospitalization
rate by gender was much the same in 2015, indicating a
marked reduction in the hospital admissions involving
females and an increase in those for males.
A previous work on HPV-related hospitalization in the
same geographical area showed that hospital admissions
for GWs increased in both genders from 2000 to 2010,
pointing to the need for prevention programs [16]. The
data emerging from the present study show a reversal of
the trend of hospital admissions for the treatment of
GWs, a number of factors might explain this picture be-
sides the increase in HPV vaccination coverage rate.
First, the hospitals (and gynecology departments in par-
ticular) in the Veneto region were reorganized in 2008;
second, changes in people’s socio-economic status may
theoretically have prompted some to go to private hospi-
tals; third, changes in healthcare-seeking behavior or
clinical practices [9] may have led to a greater use of
self-applied topical treatments for genital warts instead
of going to hospital.
The treatment strategy involves removing visible le-
sions until the host’s immune system can control viral
replication. Several methods are available for the treat-
ment of external GWs, and the choice of therapy de-
pends largely on their morphology and extent. Common
treatments include topical applications as well as surgi-
cal and obliterative approaches. Small GWs are managed
mainly at primary care services or sexual health clinics,
but larger lesions often need to be managed in the oper-
ating room by anogenital surgeons or gynecologists [17].
During the study period, there were fewer hospitaliza-
tions for penile warts than for vulvar/vaginal warts, and
this may reflect a tendency for the former to be treated
outside the hospital, since other studies found that abla-
tive treatments were more often provided outside the
hospital for men, whereas such procedures in woman re-
quired hospitalization [18, 19].
Our findings show a significant reduction over time in
the hospitalizations for vulvar/vaginal warts, especially
in the latter period (2013-2015), for patients from 12 to
20 years old, the age group for which the overall HPV
vaccination coverage had reached about 75%. An ex-
ample of the effectiveness of vaccination was seen in
Australia, where the implementation of a vaccination
program with 4HPV vaccine led to the decline and
nearly to the disappearance of GWs in both men and
women <21 years old [20, 21], and the same trend was
seen for other, more complete surveillance systems [22].
Among the males in our sample (who had yet to be
included in our regional vaccination strategy), the
hospitalization rate for penile warts decreased among 12-
to 20-year-olds, possibly suggesting a herd immunity [23].
On the other hand, the age- and gender-specific pat-
terns in the declining numbers of penile and vaginal/
vulva warts was not seen in the case of anal warts. This
may have to do with differences in sexual practices, in-
cluding the possibility of bisexuality and homosexuality
(especially among males). Men who have sex with men
(MSM) are a major risk group for sexually-transmitted
diseases, and they have a high prevalence of anal warts
due both to a greater susceptibility of the anal mucosa
by comparison with the epithelium of the penis, and to a
longer duration of anal HPV infections [24, 25]. The risk
of anal HPV infection is 4-10 times higher among MSM
than for heterosexual men. In addition to vaccinating
this higher-risk group, it is very important to make more
effort in terms of behavioral interventions to reduce the
HPV infection rate in MSM [26–28].
It will be interesting to see if the male vaccination
program introduced in our area in 2015 has any ef-
fect on the prevalence of GWs among males, includ-
ing MSM, in future.
Our study has some limitations. For a start, we should
consider the risk of the total number of HPV cases
identified being inaccurate due to coding errors in the
hospital records, although checking for the presence of
relevant surgical codes should contain this selection bias.
Another limitation lies in that the diagnoses could not
be verified due to the lack of cytological and virological
data. Finally, HDRs are unable to collect data that might
have enabled us to ascertain the sexual practices of the
study population.
Conclusions
Our data suggest an early decline in the rate of GW-
related hospital admissions in a population with a good
HPV vaccination coverage. Routinely-recorded clinical
data can be very useful for monitoring the impact of vac-
cination programs, but further efforts should be made to
establish methods for better estimating the epidemio-
logical picture regarding HPV-related diseases with par-
ticular regard to sexual behavioral.
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